GAO 3-02
Alternative Names: GAO-3-02Latest Information Update: 08 Jul 2021
Price :
$50 *
At a glance
- Originator GAOMA Therapeutics
- Class Antidementias; Antiepileptic drugs; Lipids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epilepsy
- Research Alzheimer's disease
Most Recent Events
- 06 Jul 2021 Early research in Alzheimer's disease in France (unspecified route) before July 2021 (GAOMA Therapeutics pipeline, July 2021)
- 06 Jul 2021 Preclinical trials in Epilepsy in France (unspecified route) before July 2021 (GAOMA Therapeutics pipeline, July 2021)
- 06 Jul 2021 Interim pharmacodynamics data from a preclinical study in Epilepsy released by GAOMA Therapeutics (GAOMA Therapeutics website, July 2021)